Approval status varies by treatment
Editorially reviewed · Last updated September 8, 2026 · How we review
Part of Weight Loss Drug Comparison Index.
Key findings
- Wegovy is approved; retatrutide remains investigational. No completed direct study establishes which is better.
- Retatrutide targets GLP-1, GIP, and glucagon; Wegovy contains the GLP-1 receptor agonist semaglutide.
- The often-quoted 28.7% TRIUMPH-4 and 14.9% STEP 1 results use different populations and analyses. STEP 1 does not represent every current Wegovy formulation.
- Wegovy includes 25 mg oral tablets and 7.2 mg Wegovy HD injection. The oral formulation requires fasting instructions.
- Wegovy has cardiovascular risk-reduction evidence for adults with established cardiovascular disease and overweight or obesity; retatrutide outcome studies remain ongoing.
Retatrutide vs Wegovy: Triple Agonist vs GLP-1
Wegovy is approved; retatrutide is investigational. Retatrutide and semaglutide have reported different average weight-loss results in separate trials, but those figures do not establish a head-to-head advantage. Wegovy now includes oral tablets and injectable options, including Wegovy HD. Its cardiovascular indication is another important distinction for eligible adults with established cardiovascular disease.
Side-by-Side Comparison
| Retatrutide | Wegovy (Semaglutide) | |
|---|---|---|
| Mechanism | Triple agonist: GLP-1 + GIP + Glucagon | GLP-1 receptor agonist only |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Selected trial weight loss | -28.7% at 68 weeks (TRIUMPH-4, 12 mg) | -14.9% at 68 weeks (STEP 1, 2.4 mg) |
| Administration | Once-weekly injection | Once-weekly injection OR daily oral pill |
| Oral option | None | Yes — Wegovy oral approved Dec 2025 |
| FDA status | Not approved (Phase 3) | Approved (June 2021) |
| CV outcomes | Dedicated TRIUMPH-Outcomes trial ongoing | 20% MACE reduction proven (SELECT) |
| Discontinuation (AEs) | 18.2% (12 mg) | 7.0% |
| Dysesthesia | 20.9% at 12 mg | Reported in the current label |
| Monthly cost | No approved product or announced price | Varies by formulation and eligibility; check current Wegovy costs |
How the Mechanisms Differ
Wegovy (semaglutide) targets the GLP-1 receptor only. It suppresses appetite through hypothalamic signaling, slows gastric emptying, enhances insulin secretion, and reduces glucagon release. It works primarily by reducing how much you eat.
Retatrutide also activates GIP and glucagon receptors. Preclinical findings support effects on energy expenditure and liver fat metabolism, while human studies have measured weight and liver-fat reductions. These studies do not isolate the effect of each receptor or prove superiority over semaglutide. Retatrutide liver-fat trial.
Receptor differences help explain the research rationale, not a proven twofold clinical advantage. For details, see How Does Retatrutide Work?.
Weight Loss Comparison
Swipe sideways to see every column.
| Drug | Trial | Duration | Weight Loss |
|---|---|---|---|
| Retatrutide 12 mg | TRIUMPH-4 (Phase 3) | 68 weeks | -28.7% |
| Retatrutide 9 mg | TRIUMPH-4 (Phase 3) | 68 weeks | -26.4% |
| Semaglutide 2.4 mg | STEP 1 | 68 weeks | -14.9% |
| Semaglutide 7.2 mg (Wegovy HD) | STEP UP | 72 weeks | -20.7% |
Weight Loss Thresholds
TRIUMPH-4 reported that 58.6% of the 12 mg group lost at least 25% of body weight under its efficacy analysis. The cited topline release does not provide every lower threshold. No matching head-to-head threshold comparison with Wegovy is available.
These are separate-trial results, not personal forecasts. TRIUMPH-4's 28.7% and STEP UP's 20.7% use efficacy analyses assuming treatment adherence; STEP 1's 14.9% uses a treatment-policy analysis. Differences in populations, doses and handling of treatment discontinuation prevent a direct ranking. The FDA approved Wegovy HD 7.2 mg on March 19, 2026, so STEP 1's 2.4 mg result is not a maximum for every Wegovy formulation. FDA approval, STEP UP announcement.
Cardiovascular Protection: Wegovy's Advantage
Wegovy has a proven cardiovascular benefit that retatrutide does not yet have:
The SELECT Trial — a landmark study showing semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% relative to placebo in adults with established cardiovascular disease and overweight or obesity without diabetes. This supports a specific cardiovascular risk-reduction indication.
Retatrutide's TRIUMPH-Outcomes trial is ongoing. Blood-pressure changes are not equivalent to fewer heart attacks or strokes. The cardiovascular-event estimates reported in TRIUMPH-3 did not establish cardiovascular protection. TRIUMPH-3 results.
Wegovy's Oral Formulation
In December 2025, the FDA approved oral Wegovy (semaglutide 25 mg tablet) — the first oral GLP-1 for weight loss. This eliminates the injection barrier:
- Efficacy: 16.6% average weight loss in OASIS 4 under an analysis assuming participants remained on treatment
- Cost: depends on dose, coverage and the current savings-program terms
- Fasting is required: the label specifies an empty stomach in the morning and a wait of at least 30 minutes before food, beverages or other oral medicines
The current Wegovy prescribing information gives the complete tablet instructions. Retatrutide is being studied as a weekly injection; the cited clinical program does not establish an oral retatrutide option.
Side Effects Comparison
| Retatrutide 12 mg | Wegovy 2.4 mg | |
|---|---|---|
| Nausea | 43% | 44% |
| Diarrhea | 33% | 30% |
| Vomiting | 21% | 24% |
| Discontinuation (AEs) | 18.2% | 7.0% |
| Dysesthesia | 20.9% | Reported in the current label |
Both programs reported gastrointestinal adverse events. The discontinuation figures come from different trials and do not establish which drug an individual will tolerate better. Dysesthesia is not unique to retatrutide: Wegovy's current label reports altered skin sensations with both injectable and oral formulations. Wegovy label, section 6.1.
Wegovy's advantage: over 5 years of real-world safety data from millions of patients, compared to retatrutide's trial-only experience.
Frequently Asked Questions
Is retatrutide better than Wegovy?
There is no reported head-to-head trial establishing that retatrutide is better than Wegovy. The often-quoted 28.7% and 14.9% figures come from different trials and analyses, and Wegovy now has a higher-dose injectable option as well. Wegovy is approved, with a cardiovascular indication for eligible patients; retatrutide is still investigational.
Should I wait for retatrutide or start Wegovy now?
Discuss currently approved options with your clinician. Lilly plans a Q1 2027 retatrutide submission, but approval and availability have not been established. A treatment decision should reflect your current health needs and the medicine's approved indications. See When Will Retatrutide Be Available?.
Can I switch from Wegovy to retatrutide later?
No studies have examined switching from semaglutide to retatrutide. If retatrutide is approved, your doctor could potentially transition you, but switching protocols have not been established.
Sources
-
Novo Nordisk. (2026). Wegovy prescribing information: tablet instructions, approved formulations and dysesthesia. Current label.
-
U.S. Food and Drug Administration. (2026). Wegovy HD approval. March 19 announcement.
-
Eli Lilly. (2026). Retatrutide status and TRIUMPH-3 cardiovascular-event analyses. Release.
-
Wilding, J.P.H., et al. (2021). Semaglutide 2.4 mg for the Treatment of Obesity (STEP 1). NEJM. DOI: 10.1056/NEJMoa2032183.
-
Lincoff, A.M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM. DOI: 10.1056/NEJMoa2307563.
-
Eli Lilly. (2025). TRIUMPH-4 results. Press release.
-
Novo Nordisk. (2025). Wegovy Oral FDA Approval. Press release.
How we keep this honest
- What this is
- Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
- Regulatory status
- Wegovy is FDA-approved in specific oral and injectable formulations. Retatrutide remains investigational and has no approved prescribing label.
- Our standard
- Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
- No commercial ties
- We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.
Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.
Sources
Grounded in primary sources
NEJM
The Lancet
JAMA
FDA
ClinicalTrials.govRelated reading
Comparison
Zepbound vs Wegovy: Which One Actually Works Better in 2026?
Zepbound produced -20.2% vs Wegovy's -13.7% weight loss in the SURMOUNT-5 head-to-head trial. Full comparison of cost, side effects, and CV data.
Comparison
Ozempic vs Wegovy: Same Drug, Different Purpose
Same active ingredient, different product labels: Ozempic and Wegovy injections and tablets, including Wegovy HD.
Explainer
What Is Retatrutide (GLP-3)?
Eli Lilly’s investigational triple receptor agonist: how it works, what trials show, and why GLP-3 is an informal nickname.
Keep exploring
Explore all compare topics →